Ionis Pharmaceuticals, Inc. reported $874M of revenue over the trailing twelve months, −7.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $874M (to Q2 2026). Net income: −$565M, trailing twelve months to Q2 2026. Free cash flow: −$561M, trailing twelve months to Q2 2026. Operating margin: −73%, trailing twelve months to Q2 2026.

IONSIonis Pharmaceuticals, Inc.

Healthcare

$45.26-26% 1Y

$45.26

$43.3052 weeks$86.50

IONS as reported

Ionis Pharmaceuticals, Inc. reported $874M of revenue over the trailing twelve months, −7.4% on the year before. 11 reported series are charted on this page, each one as filed.

$874M

Revenue, trailing twelve months · to Q2 2026 · −7.4% against the twelve months before

Net income: −$565M
Net income · +111% year on year · trailing twelve months to Q2 2026
Free cash flow: −$561M
Free cash flow · +93% year on year · trailing twelve months to Q2 2026
Operating margin: −73%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IONS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$874M	−7.4%	Q2 2026
Net income	−$565M	+111%	Q2 2026
EPS	−$3.46	+88%	Q2 2026
Gross margin	98%	n/a	Q2 2026
Operating margin	−73%	n/a	Q2 2026
Net margin	−69%	n/a	Q2 2026
ROE	−79%	n/a	Q2 2026
ROA	−12%	n/a	Q2 2026
ROIC	−36%	n/a	Q4 2019 · 26 quarters behind
Free cash flow	−$561M	+93%	Q2 2026
P/E	50.7	n/a	Q3 2020 · 23 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.